- Fragile X
- Treatment & Intervention
- Support the NFXF
Our latest podcast features Robert Miller of the National Fragile X Foundation and representatives of the the major pharmaceutical companies involved in ongoing Fragile X Clinical Trials. We have Dr. Paul Wang, Vice President, Clinical Development of Seaside Therapeutics; Dr. Eriene Wasef, Associate Clinical Director of Hoffman-La Roche; and Dr. Marla Hochfeld, Executive Medical Director of Novartis. Listeners will hear insightful answers to the following questions:
The NFXF encourages you to view our newest site feature, a state-by-state listing of clinical trials being conducted of potential new drugs for the treatment of fragile X syndrome and see if one might be right for you.